A groundbreaking study published in Oncoscience reveals a novel pancreatic cancer treatment strategy that targets both microtubules and mitochondria in pancreatic ductal adenocarcinoma (PDAC). Led by Michael W. Spinrad and Evan S. Glazer from the University of Tennessee Health Science Center, the research highlights the effectiveness of an experimental compound, SB-216, in reducing the growth of PDAC cells.
Pancreatic ductal adenocarcinoma is one of the deadliest cancers, often resistant to traditional treatments like chemotherapy. The study proposes a dual-targeting approach, focusing on the microtubules that support cell division and the mitochondria responsible for energy production, both of which are critical in cancer cell survival.
How SB-216 Targets Cancer Cells
SB-216 works by binding to tubulin, a key protein in microtubules, and inhibiting the overexpression of certain microtubule-associated proteins like βIII- and βIVb-tubulin, which are linked to drug resistance in pancreatic cancer. This action results in decreased cancer cell viability and slower proliferation.
In addition to its effects on microtubules, SB-216 also disrupts mitochondrial function by lowering the expression of BRD4, a protein involved in energy regulation. This interference with mitochondrial activity reduces oxygen consumption in cancer cells, triggering autophagy and mitophagy, cellular processes that remove damaged components and help regulate survival.
Promising Preclinical Results
The results of this preclinical study suggest that SB-216 is more effective than Veru-111, another compound tested in the study. SB-216’s dual-action mechanism could provide a more robust defense against PDAC, preventing cancer cells from adapting to treatment.
While these findings were obtained through in vitro experiments, further studies in animal models are necessary to confirm SB-216’s safety, efficacy, and potential as a new therapeutic approach for pancreatic cancer.
